-
RELATION NAME
-
2. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients. J Clin Oncol 28:1247-1253. © 2010 by American Society of Clinical Oncology.
-
3. Chun-Nan Yeh, Yen-Yang Chen, Jeng-Hwei Tseng et al.: Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Tajwan. Translational Oncology Volume 4 Number 6 December 2011; pp. 328-35.
-
4. Xiaofei Zhi, Xiaoying Zhou, Weizhi Wang, Zekuan Xu: Practical Role of Mutation Analysis for Imatinib Treatment in Patients With Advanced Gastrointestinal Stromal Tumors: A Meta-Analysis. PLOS ON E | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e79275.
-
RELATION NAME
-
6. Kang HJ, Ryu MH, Kim KM et al.: Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Acta On c o l 2 0 1 2 A p r ; 5 1 ( 4 ) : 5 2 8 - 3 6 . d o i : 10.3109/0284186X.2011.636753. Epub 2011 Dec 7.
-
RELATION NAME
-
RELATION NAME
-
9. Cassier PA, Fumagalli E, Rutkowski P et al.: and Hohenberger Pfor the European Organisation for Research and Treatment of Cancer. Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. Clin Cancer Res 2012;18:4458-4464. Published Online- First June 20, 2012.
-
RELATION NAME